Ebola/Marburg Vaccine Studies 

In 2009, MUWRP launched the first Ebola vaccine clinical trial to be conducted in Africa, using an early-generation DNA vaccine candidate developed by the U.S. NIH’s Vaccine Research Center (VRC), RV247. The results were published in 2014 in The Lancet and helped lead to a clinical evaluation of a more potent ChAd3 vaccine, co-developed by the VRC, National Institutes of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKine.

In 2015, MUWRP began a Phase 1b clinical trial study using the ChAd3 vaccine. The study enrolled 90 participants and about 30 volunteers from the RV247 trial will receive a boost, or additional injection, of the ChAd3 vaccine to explore the more long-lasting effect of the vaccination.

In 2015, another multisite Ebola vaccine study, referred to as EBOVAC 2, began in the US and Africa, and MUWRP is one of the study sites. It is a phase I/IIa trial to test the safety, tolerability and immunogenicity of prime-boost regimens of the candidate vaccines Ad26.ZEBOV and MVA-BN-Filo.

In 2016 the U.S. Military HIV Research Program is launching a multi-site study using these same Ad26/MVA vaccines, and MUWRP is one of the study sites.

Long-term Follow-up Study

MUWRP researchers continue to learn from past Ebola outbreaks. In 2015, they published a paper on the largest, long-term follow up study on Ebola survivors of the 2007-2008 Bundibugyo ebolavirus (BDBV) outbreak in Uganda, which showed long-term adverse health effects of the virus last more than two years.